Wall Street brokerages expect Horizon Pharma (NASDAQ:HZNP) to announce earnings per share (EPS) of $0.11 for the current quarter, Zacks reports. Two analysts have issued estimates for Horizon Pharma’s earnings, with the lowest EPS estimate coming in at $0.03 and the highest estimate coming in at $0.35. Horizon Pharma reported earnings of $0.21 per share during the same quarter last year, which indicates a negative year over year growth rate of 47.6%. The firm is scheduled to report its next earnings report before the market opens on Wednesday, May 9th.
According to Zacks, analysts expect that Horizon Pharma will report full year earnings of $1.43 per share for the current year, with EPS estimates ranging from $1.26 to $1.60. For the next financial year, analysts forecast that the company will report earnings of $1.77 per share, with EPS estimates ranging from $1.35 to $2.06. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.07. The company had revenue of $274.22 million for the quarter, compared to analyst estimates of $264.48 million. Horizon Pharma had a positive return on equity of 18.44% and a negative net margin of 38.87%. Horizon Pharma’s revenue for the quarter was down 11.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.64 earnings per share.
A number of brokerages have recently issued reports on HZNP. Cantor Fitzgerald set a $17.00 target price on Horizon Pharma and gave the stock a “buy” rating in a research report on Monday, January 8th. BidaskClub upgraded Horizon Pharma from a “sell” rating to a “hold” rating in a report on Saturday, March 3rd. ValuEngine downgraded Horizon Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. Mizuho upgraded Horizon Pharma from a “neutral” rating to a “buy” rating and lifted their price target for the company from $12.00 to $18.00 in a report on Friday, January 12th. Finally, Morgan Stanley lifted their price target on Horizon Pharma from $14.00 to $16.00 and gave the company an “equal weight” rating in a report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $18.64.
Several hedge funds have recently modified their holdings of the company. William Blair Investment Management LLC grew its holdings in shares of Horizon Pharma by 12.2% during the fourth quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock valued at $128,861,000 after buying an additional 958,414 shares in the last quarter. Sterling Capital Management LLC purchased a new position in Horizon Pharma in the fourth quarter valued at about $1,340,000. Segall Bryant & Hamill LLC grew its stake in Horizon Pharma by 12.6% in the fourth quarter. Segall Bryant & Hamill LLC now owns 725,002 shares of the biopharmaceutical company’s stock valued at $10,585,000 after purchasing an additional 81,074 shares in the last quarter. Redmile Group LLC purchased a new position in Horizon Pharma in the fourth quarter valued at about $292,000. Finally, Cowen Inc. purchased a new position in Horizon Pharma in the fourth quarter valued at about $781,000. Institutional investors and hedge funds own 86.50% of the company’s stock.
Shares of Horizon Pharma stock traded up $0.23 on Monday, reaching $13.94. 1,557,702 shares of the company were exchanged, compared to its average volume of 1,829,990. The firm has a market capitalization of $2,261.81, a PE ratio of 11.81, a price-to-earnings-growth ratio of 0.58 and a beta of 1.24. The company has a quick ratio of 1.54, a current ratio of 1.63 and a debt-to-equity ratio of 1.91. Horizon Pharma has a fifty-two week low of $9.45 and a fifty-two week high of $16.02.
WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/23/0-11-eps-expected-for-horizon-pharma-hznp-this-quarter.html.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Get a free copy of the Zacks research report on Horizon Pharma (HZNP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.